American Association for Cancer Research
The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.
Targeted therapies used to treat hematologic malignancies can cause unintended cardiac toxicity in some patients and can lead to cardiac-related mortality, according to study results presented at the American Association for Cancer Research Annual Meeting.
Results 1 - 3 of 3